UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________________________
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
____________________________________________________________
Date of
Report (Date of earliest event reported): August 4,
2017
MEDOVEX CORP.
(Exact
Name of Registrant as Specified in Charter)
|
Nevada
|
|
333-198621
|
|
46-3312262
|
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission File
Number)
|
|
(IRS
Employer Identification No.)
|
|
|
|
|
|
|
|
3060
Royal Blvd South, Suite 150
Alpharetta,
GA
|
|
|
|
30022
|
|
(Address of
principal executive offices)
|
|
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (844) 633-6839
____________________________________________________________
Copies
to:
Harvey
Kesner, Esq.
Arthur
S. Marcus, Esq.
Sichenzia
Ross Friedman Ference LLP
61
Broadway, 32nd Floor
New
York, New York 10006
(212)
930-9700
(212)
930-9725 (fax)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
□
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
□
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
□
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d
2(b))
□
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing.
On July
31, 2017, Medovex Corp. (the “Company”) received a
letter from the Listing Qualifications Department of the NASDAQ
Stock Market (the “Panel”) notifying the Company that
the Panel had determined to allow the Company to remain listed on
the NASDAQ Capital Market. The Company’s continued listing on
NASDAQ is subject to the Company advising the Panel of developments
related to its Capital raising efforts and providing certain
financial projections by October 15, 2017 and the Company showing
that it has stockholders’ equity of over $2.5 million by
November 13, 2017 or it faces potential delisting.
The
Company expects to continue to exercise diligent efforts to
maintain the listing of its common stock on NASDAQ. As such, the
Company intends to continue to timely provide NASDAQ with any and
all required materials to maintain its listing. While confident in
already ongoing initiatives which the Company believes will provide
a sustainable solution to maintaining compliance with NASDAQ
Listing Rule 5550(b)(I) related to stockholders equity, the Company
must advise investors that there can be no reasonable assurance
that the Company will be able to maintain compliance.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Date: August 4,
2017
|
MEDOVEX
CORP.
By:
/s/ Jarrett
Gorlin
Jarrett Gorlin
Chief
Executive Officer
|